The prevalence of HFpEF is rising, increasing from 33 to 39% between 2005 and 2010, with projections suggesting it will soon become the most common form of HF [5, 6]
Constipation happens less compared to nausea and diarrhea, but clinical trials and real-world data still report it
Consult a doctor before taking Coenzyme Q10+l Carnitine if you are pregnant or breastfeeding
These landmark studies established that semaglutide's weight-loss benefits are robust and measurable in non-diabetic populations
Table of Contents Understanding Mounjaro and Its Gastrointestinal Effects Mounjaro (tirzepatide) is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus and, more recently, for weight management in adults with obesity (BMI 30 kg/m) or overweight (BMI 27 kg/m) with weight-related comorbidities
People with type 2 diabetes often do not produce enough insulin or their bodies do not respond well to it